B-MS ties knot with Duke University on R&D
Bristol-Myers Squibb has forged a partnership with Duke University in the USA that will see the academic institution work more closely with the company on a broad range of drug development projects.
B-MS and the Duke Translational Medicine Institute (DTMI) have already worked together for years on areas of cardiology, endocrinology and cancer research, but will now take this to a higher level of interactivity across even more therapeutic categories.
For the first project, DTMI researchers will work with Bristol-Myers Squibb scientists on the clinical development of BMS-986202, an orally available lysophosphatidic acid 1 (LPA1) receptor antagonist under investigation to treat idiopathic pulmonary fibrosis (IPF), a chronic, progressive form of lung disease characterized by scarring of lung tissue with limited treatment options.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze